EGFR KINASE INHIBITOR AND APPLICATION THEREOF IN PREPARING ANTI-CANCER DRUG

Title:

EGFR KINASE INHIBITOR AND APPLICATION THEREOF IN PREPARING ANTI-CANCER DRUG

Document Type and Number:

WIPO Patent Application WO/2020/228635

Kind Code:

A1

Abstract:

Disclosed are an EGFR kinase inhibitor and application thereof in preparing an anti-cancer drug; said EGFR kinase inhibitor reduces the alkalinity of EGFR TKI, can effectively improve the acquired drug resistance of EGFR TKI caused by the accumulation of SQSTM1, and is of great significance to improving the clinical treatment benefits of EGFR TKI.

Inventors:

JIN HONGCHUAN (CN)
FENG LIFENG (CN)
YING SHILONG (CN)
WANG XIAN (CN)

Application Number:

PCT/CN2020/089390

Publication Date:

November 19, 2020

Filing Date:

May 09, 2020

Export Citation:

Click for automatic bibliography generation Help

Assignee:

UNIV ZHEJIANG (CN)

International Classes:

C07D413/12; A61K31/506; A61K31/517; A61K31/519; A61P35/00; C07D403/04; C07D417/12

Foreign References:

CN103102342A	2013-05-15
CN102775356A	2012-11-14
CN102947316A	2013-02-27
CN108017620A	2018-05-11
CN107793413A	2018-03-13
CN106995437A	2017-08-01
CN108558832A	2018-09-21

Other References:

ZHANG, XUAN: "The design and synthesis of a new class of RTK/HDAC dual- targeted inhibitors", MOLECULES, vol. 18, 3 June 2013 (2013-06-03), pages 6491 - 6503, XP055400177, DOI: 10.3390/molecules18066491
PRAJAPATI, BHAVESH: "Synthesis and preliminary in-vitro cytotoxic activi- ty of morpholino propoxy quinazoline derivatives", INTERNATIONAL JOURNAL OF CHEMTECH RESEARCH, vol. 6, no. 1, 31 December 2014 (2014-12-31), pages 547 - 555, XP055753551

Attorney, Agent or Firm:

ZHEJIANG HANGZHOU JINTONG PATENT AGENCY CO., LTD (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: CURVED-SURFACE LENS AND DISPLAY DEVICE

Next Patent: TRAINING METHOD AND APPARATUS, DIALOGUE PROCESSING METHOD AND SYSTEM, AND MEDIUM